Canopy Growth's Stock Just Dropped -- Here's Why I'm Still Not Buying

Canopy Growth remains deeply unprofitable, with latest quarterly revenue of C$54.5 million versus a net loss of nearly C$45.8 million, and the article argues its March acquisition of profitable MTL Cannabis for C$125 million will not materially change the picture. The company continues to face regulatory and competitive headwinds in Canada and the U.S., and the author expects more dilutive share issuances. The piece is explicitly negative on CGC stock and on the broader cannabis sector.

Analysis

This is less a one-off bearish note on CGC than a reminder that the equity remains a financing vehicle masquerading as an operating business. The second-order effect is that every incremental attempt to “fix” the balance sheet via M&A or capital raises likely comes at the expense of per-share economics, so any headline progress in revenue can still be value-destructive if it requires stock consideration or keeps the company in a chronic cash-burn cycle. In that setup, the equity is more sensitive to dilution risk than to modest operating improvement, which is why rallies tend to fade quickly.

The MTL acquisition matters mainly as a signal, not for its earnings contribution. A small profitable asset cannot materially offset a much larger legacy loss profile, so the market should treat this as a proof-of-concept for management’s preference to buy earnings rather than organically solve the core problem. That usually works only when the buyer has a strong currency and low leverage; CGC has neither, making future deals more likely to be low-quality rollups or distressed financings than true accretion.

The broader sector read-through is mixed: U.S. MSOs likely benefit at the margin from federal tax relief, but that also raises the bar for Canadian names to compete on economics and capital access. If U.S. reform continues piecemeal, the relative advantage shifts further toward better-capitalized operators with domestic scale, while weaker balance sheets become trapped in a negative loop of low growth, high cost of capital, and recurring dilution. Consensus may be underestimating how long that gap can persist even in a more favorable regulatory backdrop.

Key Decisions for Investors

• Short CGC on rallies over the next 1-3 months; use a tight risk cap because any speculative squeeze can be violent, but the asymmetry still favors downside as dilution remains the dominant catalyst.
• Prefer a relative-value long TLRY / short CGC pair for 1-2 quarters only if you want sector exposure; TLRY is not high quality, but CGC’s financing overhang is a materially worse setup.
• Avoid initiating long CGC equity until there is evidence of self-funded positive free cash flow; a 12-18 month horizon is more appropriate than trading headline-driven bounces.
• For options, consider CGC put spreads 3-6 months out to express downside while limiting premium decay; this is cleaner than outright shorting if borrow is tight or sentiment turns squeeze-prone.
• If seeking cannabis exposure, rotate toward U.S.-centric operators with demonstrated tax-rate relief benefit rather than Canadian turnarounds; the risk/reward is better where regulatory tailwinds actually hit per-share economics.